Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-755 extension study in severe congenital thrombotic thrombocytopenic purpura
CTR20213338Phase 3Active
- Sponsor
- Baxalta
- Start
- Mar 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Apadamtase alfa in Upshaw-Schulman syndrome (USS), sponsored by Baxalta. Started Mar 2022; status: active.
02
Drugs
Apadamtase alfa
03
Conditions
Upshaw-Schulman syndrome (USS)
Beyond the preview
Go deeper on CTR20213338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213338.